Pilot trial of selecting molecularly guided therapy for patients with non-V600 BRAF-mutant metastatic melanoma: Experience of the SU2C/MRA melanoma dream team

Molecular Cancer Therapeutics

Volumn 14, Issue 8, 2015, Pages 1962-1971

  LoRusso, Patricia M ^a,b   Boerner, Scott A ^a,b   Pilat, Mary Jo ^b   Forman, Karen M ^a,b   Zuccaro, Clarice Y ^b   Kiefer, Jeffrey A ^c   Liang, Winnie S ^c   Hunsberger, Sally ^d   Redman, Bruce G ^e   Markovic, Svetomir N ^f   Sekulic, Aleksandar ^g   Bryce, Alan H ^g   Joseph, Richard W ^h   Cowey, C Lance ⁱ   Fecher, Leslie Anne ^e   Sosman, Jeffrey Alan ^j   Chapman, Paul B ^k   Schwartz, Gary K ^l   Craig, David W ^c   Carpten, John D ^c   Trent, Jeffrey M ^c   more..

^a YALE CANCER CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^f MAYO CLINIC   (United States)

^g MAYO CLINIC   (United States)

^h MAYO CLINIC   (United States)

ⁱ BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^j VANDERBILT UNIVERSITY   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l Och Spine at New York Presbyterian Hospitals   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 3 (2,3 DIHYDROXYPROPYL) 6 FLUORO 5 (2 FLUORO 4 IODOANILINO) 8 METHYLPYRIDO[2,3 D]PYRIMIDINE 4,7 DIONE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; ALISERTIB; AMG 337; ANTINEOPLASTIC AGENT; AXITINIB; B RAF KINASE; BMS 906024; BOSUTINIB; BRIVANIB; CABOZANTINIB; DACOMITINIB; LINSITINIB; MLN 1117; MLN 2480; NIVOLUMAB; PLX 3397; SAPANISERTIB; TRAMETINIB; TRANSCRIPTOME; UNCLASSIFIED DRUG; UPROSERTIB; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DNA EXTRACTION; FEASIBILITY STUDY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENOME; HUMAN; HUMAN TISSUE; INTERVENTION STUDY; MEDICAL INFORMATION; MEDICAL LITERATURE; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; PERSONAL EXPERIENCE; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RNA EXTRACTION; TASK PERFORMANCE; TREATMENT PLANNING; TUMOR BIOPSY; CLINICAL TRIAL; FEMALE; GENETICS; MALE; MELANOMA; MIDDLE AGED; MUTATION; PHENOTYPE; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; PHENOTYPE; PILOT PROJECTS; PROTO-ONCOGENE PROTEINS B-RAF; TREATMENT OUTCOME;

EID: 84942155441     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0153     Document Type: Article

References (35)

1. Braiteh F, Kurzrock R. Uncommon tumors and exceptional therapies: paradox or paradigm? Mol Cancer Ther 2007;6:1175-9.
2. Stewart DJ, Kurzrock R. Cancer: the road to Amiens. J Clin Oncol 2009;27:328-33.
3. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012;485:502-6.
4. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012;150:251-63.
5. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012;44:1006-14.
6. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505:495-501.
7. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.
8. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 2012;7:e35309.
9. Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer 2011;47:2150-7.
10. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
11. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
12. Sznol M, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol 32:5s, 2014 (suppl; abstr LBA9003).
13. Ribas A, Hodi F, Kefford R, Hamid O, Daud A, Wolchok JD, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol 32:5s, 2014 (suppl;abstrLBA9000).
14. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013;14:249-56.
15. Sosman JA, Kittaneh M, Lolkema M, Postow MA, Schwartz G, Franklin C, et al. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activity. J Clin Oncol 2014;32:abstr 9009.
16. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239-46.
17. Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, et al. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res 2013;19:6696-702.
18. Bauer J, Buttner P, Murali R, Okamoto I, Kolaitis NA, Landi MT, et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011;24:345-51.
19. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
20. Balakrishnan A, Bleeker FE, Lamba S, Rodolfo M, Daniotti M, Scarpa A, et al. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res 2007;67:3545-50.
21. Heng HH. Cancer genome sequencing: the challenges ahead. Bioessays 2007;29:783-94.
22. Arnedos M, Vielh P, Soria JC, Andre F. The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? J Pathol 2014;232:274-82.
23. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013;31:1806-14.
24. Von Hoff DD, Stephenson JJ Jr., Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010;28:4877-83.
25. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011;3:111ra21.
26. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012;18:6373-83.
27. Weiss GJ, Liang WS, Demeure MJ, Kiefer JA, Hostetter G, Izatt T, et al. A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges. PLoS One 2013;8:e76438.
28. Herlyn M. New dream team for melanoma therapy. Pigment Cell Melanoma Res 2012;25:279-80.
29. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5:993-6.
30. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008;36:D901-6.
31. Yale University. Molecularly targeted therapy in treating patients with melanoma that is metastatic or cannot be removed by surgery. In:ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000-2015. [Accessed June 21, 2015.] Available from: http://clinicaltrials.gov/ct2/show/NCT02094872?term=NCT02094872&rank=1 NLM Identifier: NCT02094872.
32. Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med 2015;7:283ra53.
33. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
34. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.
35. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006-17.